BioSpace News Archive

Digirad Corporation, a diversified holding company with three divisions: Healthcare, Building & Construction, and Real Estate & Investments, announced that KBS Builders, Inc. has partially re-opened its Oxford, Maine plant to manufacture wall panels for the New England market, creating a new business line for KBS.

Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company with a pipeline of clinical-stage assets designed to modulate immunological pathways across a spectrum of diseases, announced positive data from the global Phase 2 trial of mavrilimumab in giant cell arteritis (GCA)

Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO) and SIRION Biotech GmbH (“SIRION”) today announced a licensing agreement under which Mustang has acquired rights to SIRION’s LentiBOOST™ technology for the development of MB-207,

SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, announced today preliminary financial results for the third quarter of 2020 and provided a revenue outlook for the fourth quarter of 2020.

AbbVie (NYSE: ABBV) will announce its third-quarter 2020 financial results on Friday, October 30, 2020, before the market opens.

Sirtex Medical (“Sirtex”), a leading manufacturer of targeted liver cancer therapies, announced the appointment of Mr. Francis Jannot as Executive Vice President of International Sales.

Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced the first patient was implanted in its ELITE study of the InterStim™ Micro system — the only study of a rechargeable sacral neurostimulation (SNS) system to include all SNS indications for symptoms of overactive bladder

Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic tests and services for physicians treating patients with cancer, announces it has received more than 50,000 COVID-19 specimens to date for processing through its RT-PCR technology at its CLIA-certified, CAP-accredited high-complexity molecular laboratory.

ATCC, the world’s premier biological materials management and standards organization, today announced a potential 10-year, Indefinite Delivery/Indefinite Quantity (IDIQ) contract award with a ceiling value of $250 million from the Biomedical Advanced Research and Development Authority (BARDA),

Aro Biotherapeutics announced that Ionis Pharmaceuticals, Inc., the leader in RNA-targeted therapeutics, has exercised an option to acquire a license to an undisclosed antisense oligonucleotide -Centyrin drug conjugate.